Copyright
©The Author(s) 2015.
World J Transl Med. Apr 12, 2015; 4(1): 11-24
Published online Apr 12, 2015. doi: 10.5528/wjtm.v4.i1.11
Published online Apr 12, 2015. doi: 10.5528/wjtm.v4.i1.11
Figure 12 Different classes of epigenetic drugs could inhibit epithelial-mesenchymal transition which plays a crucial role in tumor progression generating both mesenchymal differentiated and stem cancer cells.
HDACi: Histone deacetylase inhibitor; DNMTi: DNA methyltransferase inhibitor; 5’Aza-C: 5-azacytidine are given as examples of demethylating agent. Adapetd by Kiesslich et al[11], 2013.
- Citation: Lattanzio L, Lo Nigro C. Epigenetics and DNA methylation in cancer. World J Transl Med 2015; 4(1): 11-24
- URL: https://www.wjgnet.com/2220-6132/full/v4/i1/11.htm
- DOI: https://dx.doi.org/10.5528/wjtm.v4.i1.11